Collaboration Revenue - Related Party was Spero Therapeutics’s largest product and service line in fiscal 2025, bringing in $47.03M of $66.80M (70%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Collaboration Revenue - Related Party | $95.80M | $27.03M | $47.03M |
| Grant | — | $20.20M | — |
| Grant Revenue | $7.05M | — | $7.18M |
| Collaboration Revenue | $933.00K | $371.00K | $12.59M |
| Spr206 | — | $400.00K | — |
| Total | $103.78M | $48.00M | $66.80M |
Spero Therapeutics brought in $66.80M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Spero Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $48.00M. Collaboration Revenue - Related Party was the largest at $47.03M (70.4%), ahead of Collaboration Revenue at $12.59M (18.8%) and Grant Revenue at $7.18M (10.8%).
Compared with fiscal 2024, Collaboration Revenue grew 3,292.5% to $12.59M and Collaboration Revenue - Related Party grew 74.0% to $47.03M. From fiscal 2023 to 2025, combined revenue from these lines fell from $103.78M to $66.80M, a compound annual decline of 19.8%. Collaboration Revenue - Related Party's share of the total fell from 92.3% to 70.4%.
Spero Therapeutics stopped reporting Grant ($20.20M in fiscal 2024) and Spr206 ($400.00K in fiscal 2024) as separate lines.
Spero Therapeutics (SPRO) reports its revenue by product and service. In fiscal 2025, Collaboration Revenue - Related Party was its largest product and service line, bringing in $47.03M (70.4% of the total), followed by Collaboration Revenue at $12.59M (18.8%).
Collaboration Revenue - Related Party was Spero Therapeutics' largest product and service line in fiscal 2025, bringing in $47.03M, or 70.4% of the $66.80M total across its three product and service lines.
Every figure comes from Spero Therapeutics' annual financial filings, as reported. Each line keeps the name Spero Therapeutics gives it, and years follow its fiscal calendar.
Spero Therapeutics' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.